teclistamab
genmab,janssen
['majestec-1', 'multiple myeloma', 'teclistamab']
#asco22 | june 5 | oral abstract session | hematologic malignancies
"teclistamab, a bcma x cd3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: updated efficacy and safety results from majestec-1"
presenter: ajay nooka, md 
As Georgia's NCI Comprehensive Cancer Center, we are at the forefront of cancer research, innovation, and discovery. Request patient appointment: (888) 946-7447